Background-Left ventricular (LV) remodeling after acute myocardial infarction is associated with adverse prognosis.
T he development of heart failure after acute myocardial infarction (AMI) is the result of left ventricular (LV) remodeling. This complex process, which has a powerful association with adverse outcome, involves changes in cardiac morphology, affecting both cellular and extracellular elements of the myocardium. Early prediction of LV remodeling and the development of heart failure after AMI is challenging and may, potentially, be improved by the identification of novel biomarkers associated with this process. Several biomarkers are associated with LV remodeling and the development of heart failure. 1 Of these, the natriuretic peptides, in particular B-type natriuretic peptide (BNP) and the N-terminal fragment of the precursor peptide, N-terminal probrain natriuretic peptide (Nt-proBNP), have prognostic value in patients with acute coronary syndromes. 2, 3 This use is enhanced by the concomitant determination of other biomarkers such as troponin I and C-reactive protein (CRP). 4 However, the prognostic value of Nt-proBNP is limited, in part, by the fact that circulating levels fluctuate considerably in the early period after AMI. 5 
Clinical Perspective on p 298
MicroRNAs (miRNAs) are short oligonucleotides expressed in a cell-and tissue-specific manner that regulate gene expression and organ function, including the myocardium. 6 Because of the discovery of their presence and stability in human peripheral blood, 7, 8 miRNAs have shown potential as circulating biomarkers of cardiovascular diseases. Several studies reported the diagnostic potential of cardiac-enriched miRNAs in the setting of AMI. 9 Other studies have reported the dysregulation of miRNA expression in the failing or hypertrophic heart [10] [11] [12] [13] and in the circulation of patients with heart failure. 14 Because miRNAs play functional roles in the development of heart failure, 15 modulation of their expression and activity has emerged as an attractive potential tool to limit the development of this condition. However, the prognostic value of miRNAs after AMI has received less attention.
In a study by Widera et al, 16 circulating levels of 6 cardiacenriched miRNAs were measured in patients with acute coronary syndrome. Levels of miR-133a and miR-208b were upregulated in patients with AMI (compared with patients with unstable angina) and were associated with the risk of death. However, this association was lost after adjustment for high-sensitivity cardiac troponin T. Interestingly, circulating miRNAs follow a typical expression profile post-AMI that may be used for prognostic purposes. 17 For instance, miR-208a increased 5 days post-AMI and remained elevated up to 90 days later. In a recent study evaluating the diagnostic value of circulating miRNAs in patients with AMI, we observed a weak association between cardiac-enriched miR-208b and miR-499 and LV dysfunction. 18 Using a systems-based approach, combining analyses of miRNA profiles, obtained by microarrays, with networks of miRNA gene interactions, we identified novel circulating miRNAs with prognostic potential after AMI. We related concentrations of candidate miRNAs to the extent of ventricular remodeling after AMI.
Materials and Methods
An expanded version of Methods is available in the online-only Data Supplement.
Patients
We studied 90 patients with first ST-segment-elevation AMI ( Table 1) . Microarray experiments were performed on plasma from a derivation cohort of 60 patients admitted to our center between September 1, 2004, and March 31, 2005 , enrolled in a prospective study of LV remodeling after AMI. 19 Over half of these patients were treated by thrombolysis; none received primary percutaneous coronary intervention, which was not in routine use at our center at the time. Cardiac function was evaluated by echocardiography, as described, 19 conducted by a single operator (D.K.) at discharge and at a median of 176 days (range, 138-262 days) after AMI.
Patients from the derivation cohort were selected according to whether they demonstrated LV remodeling post-AMI, as assessed from the change in LV end-diastolic volume (ΔEDV) between discharge and follow-up. LV remodeling was defined as any increase in LVEDV during follow-up. During this selection, patients with diabetes mellitus or a prior AMI were excluded. Patients with or without LV remodeling were matched by age and had comparable cardiovascular risk factors. The rationale for this selection procedure was to avoid any bias attributable to a potential effect of confounding factors on circulating levels of miRNAs, as previously reported. 16 Data from a distinct cohort of 30 patients with AMI were used for validation. Patients presenting with first ST-segment-elevation AMI were admitted to our center between January 4, 2010, and July 1, 2010, and treated by primary percutaneous coronary intervention. LV function and remodeling were assessed by cardiac magnetic resonance imaging as described, 20 at discharge and at a median of 121 days (range, 98-209 days). All cardiac magnetic resonance imaging examinations were performed under the supervision of a single investigator (G.M.), were analyzed by N.R., and interpretation was verified by G.M. All imaging assessment was performed by investigators blinded to natriuretic peptide and miRNA data.
In each study, the diagnosis of AMI was based on presentation with appropriate symptoms of myocardial ischemia, dynamic ST-segment elevation, and increase in markers of myocyte necrosis (creatine kinase and troponin I) to more than twice the upper limit of the normal range. Venous blood samples were collected in EDTA-aprotinin tubes immediately before discharge (day 3-4 after AMI) and at follow-up. Samples were centrifuged within 30 minutes, and plasma was stored in aliquots at −80°C.
The protocol for each study was approved by the local research ethics committee, and written informed consent was obtained from all subjects. The conduct of the study was in keeping with the Declaration of Helsinki.
Microarrays
Microarrays were used to obtain circulating miRNA expression profiles in patients with (n=30) and without (n=30) remodeling from the derivation cohort. Identical volumes of plasma obtained at discharge from the 30 patients of a group were pooled to reach a final volume of 400 µL. Total RNA was extracted using the miRVana PARIS isolation kit (Applied Biosystems, Lennik, Belgium). Hybridization was performed on miRNA Human Microarray Release 12.0 slides (Agilent Technologies, Santa Clara, CA), and 4 arrays were hybridized per group. Data are available at the Gene Expression Omnibus (www. ncbi.nlm.nih.gov/geo/) under the accession number GSE 34571.
Additional details are available in the online-only Data Supplement.
Plasma miR-150 Determination
Total RNA was extracted from plasma, and quantitative polymerase chain reaction (PCR) performed with the SYBR-green PCR kit and miR-150-specific miScript primer set (Qiagen, Venlo, the Netherlands) as described. 18 Spiked-in synthetic C elegans miRNAs were added to plasma samples for correction of extraction efficiency. Expression levels were calculated with the formula 2 exp (mean Ct spiked-in controls−Ct target miRNA).
Nt-proBNP Assay
Plasma Nt-proBNP was assayed using a noncompetitive assay, as previously described, 21 on the basis of the assay originally described by Karl et al. 22 Briefly, a C-terminal-directed antibody was immobilized onto ELISA plates, and an N-terminal antibody was affinity purified and biotinylated. Aliquots (20 μL) of samples or Nt-proBNP standards were incubated in the C-terminal antibody-coated wells in the presence of the N-terminal biotinylated antibody. After washing, plates were incubated with streptavidin labeled with methylacridinium ester and were read on a luminometer with sequential injections of nitric acid (with H 2 O 2 ) and NaOH (with cetyl ammonium bromide). The lower limit of detection was 14.4 fmol/mL. Within and between assays, coefficients of variation were 2.3% and 4.8%, respectively. There was no cross-reactivity with atrial natriuretic peptide, BNP, or C-type natriuretic peptide.
Luciferase Reporter Assay
Human embryonic kidney (HEK)293T cells maintained in Dulbecco modified Eagle medium supplemented with 10% FBS, 1% L-glutamine, and 1% penicillin-streptomycin were used for luciferase assay. Cells plated in 96-well plates were cotransfected using lipofectamine 2000 (Invitrogen, Merelbeke, Belgium) with 10 ng of reporter plasmids containing the 3′ untranslated regions of CRP or adrenergic receptor β1 (ADRB1) inserted downstream of the gaussian luciferase secreted reporter gene and the secreted alkaline phosphatase tracking gene (pEZX-MT05, GeneCopoeia, Labomics, Nivelles, Belgium) and 30 nmol/L of pre-miR miRNA precursor hsa-miR-150 (Applied Biosystems) or negative control. Gaussian luciferase and alkaline phosphatase activities were assessed by luminescence in conditioned medium 24 and 48 hours after transfection using the secreted-pair dual luminescence kit (GeneCopoeia). Gaussian luciferase activity was normalized to alkaline phosphatase activity.
Expression of miR-150 in the Murine Heart
All mice used in the present study were C57BL/6 male mice (8-10 weeks old; 20-25 g). The investigation conformed to the Guide for the Death, n (%) 1 (2) 0 (0) 1 (30 1 ACE indicates angiotensin-converting enzyme; CABG, coronary artery bypass grafting; CHF, congestive heart failure; CK, creatine kinase; EDV, end-diastolic volume; FH, familial hypercholesterolemia; MI, myocardial infarction; PCI, percutaneous coronary intervention; Nt-BNP, N-terminal pro-brain natriuretic peptide; and STEMI, ST-segment-elevation myocardial infarction.
*For comparison between ΔEDV≤0 and ΔEDV>0. †For comparison between validation cohort and whole derivation cohort. ‡The troponin I assay changed between the derivation cohort and the validation cohort; hence the different upper limits.
Care and Use of Laboratory Animals published by the US National
Institutes of Health. Animals were anesthetized with a mix of isoflurane/oxygen (2.5%-1.5%) until intubation and ventilation with 1% to 1.5% isoflurane/oxygen. Myocardial infarction was induced in 5 mice by permanently ligating the left anterior descending coronary artery after a left thoracotomy. Five mice were sham operated. Mice were euthanized 15 days after surgery. Hearts were collected, fixed in formalin during 24 hours, and embedded in paraffin. Fivemicrometer-thick sections were stained for collagen deposition with Masson trichrome. Expression of miR-150 was assessed by in situ hybridization using the miRCURY LNA miRNA ISH Optimization Kit (Exiqon, Vedbaek, Denmark) according to the manufacturer's instructions. A scramble probe was used as negative control. 
Statistical Analysis

Patient Characteristics
Prediction Analyses
Prediction analyses were performed with R version 2.14.2 with the PredictABEL package. A P value <0.05 was considered statistically significant. Clinical features were coded as 1 for presence and 0 for absence. Prediction of LV remodeling (ΔEDV>0) was assessed by logistic regression. The area under the receiver-operating characteristic curve was used to estimate the value of biomarkers to predict remodeling. The added value of miR-150 to Nt-proBNP was evaluated by analysis of deviance and was tested for significance using the Wald χ 2 test.
Reclassification Analyses
Reclassification analyses were performed, testing the predictive value for the identification of remodeling of miR-150, first together with Nt-proBNP and second together with age, sex, and admission serum markers. Logistic regression models were used for patient classification. The net reclassification index and the integrated discrimination improvement 23 were used to validate the classification performance changes for miR-150. Statistical significance was evaluated as described. 24 Table 1 shows the characteristics of patients in the derivation cohort, as a whole and divided by evidence of LV remodeling, and of the validation cohort. There were no clinically meaningful differences between the derivation and validation cohorts, other than those reflecting changes in therapeutic management of AMI between the periods of the 2 studies. Thus, there were differences in the mode of revascularization and in the frequency of prescription of clopidogrel. Accordingly, patients of the validation cohort had lower levels of Nt-proBNP than patients of the derivation cohort. Table 2 shows LV function and volumes in the derivation cohort, stratified by the presence or absence of remodeling, and in the validation cohort. Because imaging modalities differed, we did not perform formal statistical comparison of LVEF and LV volumes between the cohorts.
Results
Patient Characteristics
Within the derivation cohort, patients who subsequently developed LV remodeling were less likely to have received reperfusion therapy (thrombolysis) at presentation (Table 1) . Although not reaching conventional statistical significance, an anterior site of AMI was more prevalent among patients with remodeling. Predischarge levels of markers of myocyte necrosis (creatine kinase) and of Nt-proBNP, as well as LV ejection fractions and volumes, were similar between patients who subsequently did, or did not, show LV remodeling (Tables 1 and 2 ).
In patients who showed remodeling, absolute values for LVEDV and LV end-systolic volume were greater compared with patients without remodeling, as were the changes in these parameters between discharge and follow-up. Remodeling was associated with a small mean reduction in LVEF between discharge and follow-up compared with a small increase in the absence of remodeling.
Circulating miRNA Profiles and Remodeling After AMI
Circulating miRNAs were measured in plasma samples from all patients of the derivation cohort, stratified by the presence (ΔEDV>0; n=30) or absence (ΔEDV≤0; n=30) of remodeling. Identical volumes of plasma from each of the 30 patients of each group were pooled to reach a final volume of 400 µL for each group and processed by microarrays. Among the 695 miRNAs on microarrays, 160 were detected in 1 or both groups of patients. Twenty-nine miRNAs were detected only in patients without remodeling. Complete data are in Table I in the online-only Data Supplement.
Identification of miRNAs Potentially Involved in LV Remodeling
A systems-based approach was undertaken to select, using microarray data, which miRNAs would be most likely to be involved in the development of LV remodeling. Using the key words "ventricular remodeling" and "myocardial infarction" and a limit to "homo sapiens," we retrieved from the Entrez-Gene database a set of 13 genes known to be associated with LV remodeling. These 13 seed genes were used to query protein-protein interaction databases. Eleven of these 13 genes encoded proteins known to interact with 26 other proteins ( Figure 1A and Table II in the online-only Data Supplement). Then, we retrieved from miRNA-target databases a list of 265 miRNAs predicted to target the 13 seed genes or genes encoding the 26 interacting proteins ( Table III in the online-only Data Supplement). Using these genes and miRNAs, we built an interaction network ( Figure 1B and 1C ) in which nodes represent either proteins or miRNAs and edges represent either protein-protein interactions or miRNA-target pairs. Analyses allowed isolation of the top 10 high-traffic miRNAs (hsa-miR-27a/-133a/-625/-296-3p/-31/-23a/-204/-19a/-101/-150) predicted to regulate the expression of a high number of proteins involved in LV remodeling and therefore potentially involved in the process.
Selection of 1 Candidate miRNA
Having identified 10 miRNAs with potential role in LV remodeling, we selected miR-150 for further analysis for the following reasons. Among the top 10 high-traffic miR-NAs, miR-27a, miR-23a, miR-19a, miR-101, and miR-150 were highly expressed in microarray data. In addition, miR-101 and miR-150 were readily detected in patients without remodeling and totally absent in patients with remodeling ( Table I in the online-only Data Supplement). Higher levels of miR-101 and miR-150 in patients without remodeling were confirmed using quantitative PCR ( Figure 1D ). The observation that miR-150 was the most differentially expressed miRNA motivated its selection for further analysis. Also, it has be noted that in animal models miR-150, but not miR-101, has been shown to be regulated during cardiac hypertrophy. 12, 25 According to computational analysis, miR-150 was predicted to target 2 genes involved in LV remodeling, ADRB1 26 and CRP, 27 and 1 interacting gene, tumor necrosis factor receptor-associated factor 2 28 ( Figure 1A and Table III in the online-only Data Supplement). A luciferase assay performed in cultured cells validated the downregulation of CRP and ADRB1 by miR-150 ( Figure 1E ). 
miR-150 and Nt-proBNP: Prediction of LV Remodeling
We assessed the value of discharge levels of miR-150 and Nt-proBNP for the prediction of LV remodeling in an independent validation cohort of 30 patients after AMI. Again, patients in the validation cohort were categorized into remodeling (ΔEDV>0; n=19) and no remodeling (ΔEDV≤0; n=11). Levels of miR-150 at discharge, as assessed by quantitative PCR, were lower in patients with compared with those without remodeling (2-fold; P=0.03; Figure 2A ), confirming the results seen in the derivation cohort.
For the classification of patients into ΔEDV>0 or ΔEDV≤0 groups, area under the receiver-operating characteristic curve was 0.74 (95% confidence interval [CI], 0.55-0.94) for miR-150 and 0.60 (95% CI, 0.39-0.80) for Nt-proBNP ( Figure 2B ). The combination of Nt-proBNP and miR-150 showed an area under the receiver-operating characteristic curve of 0.77 (95% CI, 0.60-0.94). The combination of the 2 biomarkers reduced the deviance of the Nt-proBNP model by 5.6 (P=0.02).
Reclassification analyses were performed to evaluate the capacity of miR-150 to reclassify patients misclassified by Nt-proBNP. Patients were categorized into low (<50%), intermediate (50%-75%), and high (>75%) probability of remodeling groups ( Table 3 ). The net reclassification index was 54% (95% CI, 5-102; P=0.03). The integrated discrimination improvement was 0.16 (95% CI, −0.01 to 0.33; P=0.07).
Finally, reclassification analyses were performed to evaluate the added value of miR-150 over a multiparameter clinical model, including age, sex, and admission levels of troponin I, creatine kinase, and Nt-proBNP. MiR-150 was able to reclassify 59% (net reclassification index, 59%; 95% CI, 9-108; P=0.02) of patients originally misclassified by the multiparameter clinical model into remodeling (ΔEDV>0) and no remodeling (ΔEDV≤0) groups (Table 4 ). Again, the integrated discrimination improvement was of borderline statistical significance (0.17; 95% CI, −0.02 to 0.34; P=0.05).
Expression of miR-150 in the Murine Heart
To characterize the origin of miR-150, mice were subjected to MI through coronary ligation. Fifteen days after MI induction, the left ventricle was dilated, and an intense collagen deposition was visible in infarcted areas of the heart (Figure 3A and 3B). As revealed by in situ hybridization, miR-150 expression was increased in the infarct zone compared with the cardiac tissue of sham-operated mice and remote and border zones of MI mice hearts ( Figure 3C ). Using quantitative PCR, we also found a reliable expression of miR-150 in the murine heart (data not shown). Therefore, miR-150 is expressed in the heart and is upregulated in infarcted tissues.
Discussion
The present study is the first to report the identification of a miRNA biomarker of LV remodeling post-AMI using a systems-based approach, the potential use of which to identify relevant transcriptomic or proteomic biomarkers has been reported. [29] [30] [31] Using these strategies, we have recently identified several candidate biomarkers of LV remodeling post-AMI. 29 Now, we provide evidence that systems-based approaches are suitable to identify miRNAs associated with LV remodeling that can be used for prognostication purposes. Our results indicate that miR-150 has the potential to predict LV function and remodeling after MI with power comparable or superior to that of Nt-proBNP, the current gold standard biomarker for the prediction of LV dysfunction in this setting. The regulation of expression of miRNAs in disease states such as cardiac hypertrophy has been studied extensively. 32 In addition, although the diagnostic value of circulating miRNAs for acute coronary syndromes has been recently investigated, 9 their prognostic use has been far less studied. Widera et al 16 recently reported a higher risk of death for patients with elevated miR-133a or miR-208b after acute coronary syndromes. However, this predictive value was modest and was lost after adjustment for high-sensitivity troponin. We recently confirmed this finding and found a modest association between miR-208b (area under the receiver-operating characteristic curve=0.69) and LV dysfunction. 18 In the present study, we identified miR-150, a nonprototype cardiac miRNA, as a potential prognostic marker after AMI. Lower circulating concentrations of miRNA-150 were associated with LV remodeling in both our derivation and validation cohorts. This suggests a protective role for miR-150, consistent with previous studies, showing that low levels of miR-150 are associated with hypertrophy 12, 25 and LV rupture after AMI. 33 Although the prognostic value of miR-150 has been described in patients with sepsis 34 and acute leukemias, 35 this is the first study to report an association with remodeling post-AMI. The association between miR-150 and sepsis suggested a link with inflammation, as also suggested by the observation that miR-150 is expressed by monocytes. 36 Because inflammation is a critical component of the development of LV remodeling after AMI, future studies are needed to determine the role of miR-150 in this setting.
We identified miR-150 as a node in the network of miRNAs and proteins linked to LV remodeling. According to miRNAtarget databases, miR-150 is predicted to regulate the expression of 3 genes associated with LV remodeling: ADRB1, 26 CRP, 27 and tumor necrosis factor receptor-associated factor 2. 28 Using luciferase assay, we validated that miR-150 effectively regulates the expression of CRP and ADRB1. However, the interaction between miR-150 and tumor necrosis factor receptor-associated factor 2 was not tested because of the failure of cloning the 3′ untranslated region of tumor necrosis factor receptor-associated factor 2 into the reporter plasmid. The role of miR-150 in the heart is poorly characterized. miR-150 is actively secreted by circulating monocytes, is transferred to endothelial cells, and regulates their migration in a paracrine manner. 36 In addition, miR-150 targets CXCR4 in bone marrow-derived mononuclear cells, thereby regulating their mobilization and migration. 37 These observations suggest that miR-150 plays an active role in the regulation of cardiac healing, consistent with our observation that low levels of miR-150 are associated with adverse remodeling after AMI. A functional role of miR-150 after AMI is further supported by our datamining results predicting regulation by miR-150 of target genes of 3 categories linked to cardiomyopathy and hypertrophy.
We confirmed, using both quantitative PCR and in situ hybridization, that expression of miR-150 is high in the heart. Fifteen days after induction of MI in mice, miR-150 was increased in the infarct zone. This observation may contrast with the previous finding of decreased expression of miR-150 after MI in mice. 38 However, in this study, miR-150 was measured in RNA extracted from nonischemic cardiac tissue of mice 8 weeks after ligation. In our experiments, mice were euthanized 2 weeks after MI, and we observed an increase of miR-150 expression in necrotic tissues. The significance of this apparent discrepancy requires deeper mechanistic investigations. Analysis of a publicly available microarray data repository (Gene Expression Omnibus accession No. GSE 36946) revealed that miR-150 is highly expressed in cardiac tissue from patients with hypertrophic cardiomyopathy undergoing surgical myectomy and is downregulated in these patients compared with control donors. This observation is consistent with Van Rooij et al 12 , who reported that miR-150 is downregulated in the failing heart. Therefore, miR-150 measured in the bloodstream of patients after AMI originates, at least in part, from the heart. A participation of monocyte-derived miR-150 cannot be excluded, although this is not consistent with a low inflammation in patients without remodeling. It has to be mentioned that miRNAs other than cardiomyocyte-enriched miRNAs may also contribute to LV remodeling, 39 and this is in accordance with our present data.
The observed lack of prediction of LV remodeling by predischarge Nt-proBNP is perhaps surprising. However, our observations are consistent with previous findings from our group of a lack of association between Nt-proBNP and ΔEDV in a study of 404 patients during follow-up after AMI, despite Nt-proBNP being predictive of the combined end point of death or heart failure during follow-up. 40 Using reclassification analyses, we report the additive predictive power for LV remodeling for miRNA-150 to either Nt-proBNP or a multiparameter model, including serum markers at admission, age, and sex. This is perhaps unsurprising. Although circulating levels of the natriuretic peptides reflect myocardial wall stress and cardiac enzymes reflect myocardial damage, the end result of remodeling, miRNAs are a measure of the dysregulation of the processes leading to LV remodeling. Thus, miRNA-150 and serum markers give measures of different aspects of the remodeling process, which may in part explain the additive value of consideration of all biomarkers.
Limitations
The present study is limited by the relatively small numbers of patients, restricting our ability to demonstrate an association between miR-150 and clinical outcomes, which remains to be studied. Furthermore, patients of the derivation cohort were selected according to the presence or absence of remodeling during follow-up. This selection could have overestimated the discriminative capacity of miR-150. However, this is not supported by the validation of the biomarker value of miR-150 in an independent group of unselected patients. A strength of our study is the use of independent derivation and validation cohorts, the latter assessed by cardiac magnetic resonance imaging, allowing accurate assessment of LV function and volumes and reducing markedly the numbers of patients required for assessment of these parameters compared with alternative imaging modalities. Another limitation resides in the design of the systems-based approach and in the selection of the 13 genes known to be associated with LV remodeling. This selection has certainly affected the candidate miRNAs (so-called high-traffic miRNAs). Assessment of expression levels of all miRNAs in individual patients of the derivation cohort using microarrays or deep sequencing may be another approach to identify candidate miRNAs with prognostication potential.
In conclusion, miR-150 is low in the circulation of patients who experience LV remodeling after ST-segment-elevation AMI. MicroRNA-150 may be downregulated in this setting, and its measurement may facilitate early identification of patients at risk of LV remodeling, a powerful marker of adverse prognosis. The use of miRNA-150 as a clinical prognostic biomarker merits further investigation.
